Last reviewed · How we verify

Tetralogy of Fallot — Treatment Landscape & Competitive Intelligence

Tetralogy of Fallot (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tetralogy of Fallot, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Caverject ALPROSTADIL Pfizer Prostaglandin Analog [EPC] Prostaglandin E2 receptor EP3 subtype 1981-01-01
Prostavasin Prostavasin Hannover Medical School Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Hannover Medical School · 1 drug in Tetralogy of Fallot
  2. Pfizer · 1 drug in Tetralogy of Fallot

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tetralogy of Fallot:

Cite this brief

Drug Landscape (2026). Tetralogy of Fallot — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tetralogy-of-fallot. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing